v3.26.1
Summary of Significant Accounting Policies (As Restated) (Tables)
 6 Months Ended
Mar. 31, 2026
Summary of Significant Accounting Policies (As Restated) [Abstract]  
Schedule of Fair Value of Financial Instruments

The fair value of financial instruments measured on a recurring basis is as follows:

 

   As of March 31, 2026 
Description  Total   Level 1   Level 2   Level 3 
Liabilities:                
Warrant liability  $709,507   $
      -
   $
      -
   $709,507 
Total liabilities at fair value  $709,507   $
      -
   $
      -
   $709,507 

 

   As of September 30, 2025 
Description  Total   Level 1   Level 2   Level 3 
Liabilities:                
Warrant liability  $1,266,894   $
      -
   $
      -
   $1,266,894 
Total liabilities at fair value  $1,266,894   $
      -
   $
      -
   $1,266,894 
Schedule of Warrant Liability Measured at Fair Value

The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the six months ended March 31, 2026 and 2025, respectively.

 

   2026   2025 
Warrant liability        
Balance as of beginning of Period  $1,266,894   $2,140,315 
Change in fair value of warrant liability   (214,469)   (779,796)
Exercise   (342,918)   
-
 
Balance as of end of period  $709,507   $1,360,519 
Schedule of Computation of Diluted Net Loss Per Share

The table below presents the computation of basic and diluted loss per share:

 

   Three Months Ended   Six Months Ended 
   March 31,   March 31, 
   2026
(As Restated)		   2025   2026
(As Restated)		   2025 
Basic:                    
Net loss available to common stockholders - basic  $(2,382,022)  $(2,270,607)  $(3,819,912)  $(485,285)
Weighted average common shares outstanding - basic   8,484,926    5,185,075    8,436,158    5,161,971 
Loss per share - basic  $(0.28)  $(0.44)  $(0.45)  $(0.09)
                     
Diluted (1):                    
Net loss available to common stockholders - diluted  $(2,382,022)  $(2,270,607)  $(4,031,518)  $(485,285)
Weighted average common shares outstanding - diluted   8,484,926    5,185,075    8,554,213    5,161,971 
Loss per share - diluted  $(0.28)  $(0.44)  $(0.47)  $(0.09)

 

(1)For the three and six months ended March 31, 2025, no adjustment was made to the numerator and no incremental shares were added to the denominator for the PIPE Warrants being accounted for as a derivative liability as the PIPE Warrants were out-of-the-money during these periods. See “Note 13 - Stockholders’ Equity”.
Schedule of Weighted Average Common Shares

The following table presents the computation of weighted average common shares considered in the computation of diluted net loss per share during the three and six months ended March 31,

 

   Three Months Ended   Six Months Ended 
   March 31,   March 31, 
   2026   2025   2026   2025 
Denominator (weighted average shares)                
Basic common shares outstanding   8,484,926    5,185,075    8,436,158    5,161,971 
Dilutive stock options   
-
    
-
    
-
    
-
 
Dilutive restricted stock units   
-
    
-
    
-
    
-
 
Dilutive warrants   
-
    
-
    118,055    
-
 
Diluted common shares outstanding   8,484,926    5,185,075    8,554,213    5,161,971 
Schedule of Basic Net Loss Per Share as their Effect Would have Been Anti-Dilutive

The following potential common shares were not considered in the computation of basic net loss per share as their effect would have been anti-dilutive for the three and six months ended March 31, 2026 and 2025:

 

   Three Months Ended   Six Months Ended 
   March 31,   March 31, 
   2026   2025   2026   2025 
Warrants   361,111    1,174,322    243,056    1,174,322 
Stock options   1,098,038    477,561    1,098,038    477,561 
Restricted stock units   84,750    147,780    84,750    147,780